litlas
Log inCreate account

Andreas Hochhaus

Active 1994–2025

323
Papers
78,460
Citations
129
h-index
308
i10-index

Citations

Citations per year for Andreas Hochhaus1979: 29 citations1995: 3 citations1996: 9 citations1997: 9 citations1998: 15 citations1999: 25 citations2000: 31 citations2001: 29 citations2002: 93 citations2003: 247 citations2004: 215 citations2005: 233 citations2006: 318 citations2007: 478 citations2008: 497 citations2009: 571 citations2010: 508 citations2011: 627 citations2012: 597 citations2013: 552 citations2014: 541 citations2015: 562 citations2016: 574 citations2017: 439 citations2018: 409 citations2019: 1,539 citations2020: 1,765 citations2021: 1,664 citations2022: 1,366 citations2023: 1,164 citations2024: 2,424 citations2025: 910 citations2026: 12 citations1980–1994: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,913 citing papers, 24% of this breakdownGermany: 1,510 citing papers, 9.2% of this breakdownItaly: 1,156 citing papers, 7.1% of this breakdownUnited Kingdom: 1,068 citing papers, 6.5% of this breakdownChina: 1,064 citing papers, 6.5% of this breakdownFrance: 855 citing papers, 5.2% of this breakdownSpain: 514 citing papers, 3.2% of this breakdownNetherlands: 478 citing papers, 2.9% of this breakdownSwitzerland: 469 citing papers, 2.9% of this breakdownCanada: 463 citing papers, 2.8% of this breakdownJapan: 463 citing papers, 2.8% of this breakdownAustralia: 453 citing papers, 2.8% of this breakdown
0%24%Other 24.1%

Institutions

Fields

  • Medicine72.3%
  • Biochemistry, Genetics and Molecular Biology18%
  • Immunology and Microbiology4.1%
  • Computer Science1.4%
  • Materials Science0.9%
  • Chemistry0.6%
  • Other2.7%

Topics

  • Chronic Myeloid Leukemia Treatments10.2%
  • Acute Myeloid Leukemia Research6.9%
  • Chronic Lymphocytic Leukemia Research5.6%
  • Eosinophilic Disorders and Syndromes4.7%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment3.4%
  • Acute Lymphoblastic Leukemia research2.9%
  • Other66.3%

Coauthors

All papers

Open in search
  1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

    Authors: Joseph D. Khoury, Éric Solary, Oussama Abla, Yassmine Akkari, Rita Alaggio, Jane F. Apperley, Rafael Bejar, Emilio Berti, Lambert Busque, John K. C. Chan, Weina Chen, Xueyan Chen, Wee Joo Chng, John Choi, Isabel Colmenero, Sarah E. Coupland, Nicholas C.P. Cross, Daphne de Jong, M. Tarek Elghetany, Emiko Takahashi, Jean‐François Emile, Judith A. Ferry, Linda Fogelstrand, Michaëla Fontenay, Ulrich Germing, Sumeet Gujral, Torsten Haferlach, Claire Harrison, Jennelle C. Hodge, Shimin Hu, Joop H. Jansen, Rashmi Kanagal‐Shamanna, Hagop M. Kantarjian, Christian P. Kratz, Xiaoqiu Li, Megan S. Lim, Keith R. Loeb, Sanam Loghavi, Andrea N. Marcogliese, Soheil Meshinchi, Phillip Michaels, Kikkeri N. Naresh, Yasodha Natkunam, Reza Nejati, German Ott, Eric Padron, Keyur P. Patel, Nikhil Patkar, Jennifer Picarsic, Uwe Platzbecker, Irene Roberts, Anna Schuh, William A. Sewell, Reiner Siebert, Prashant Tembhare, Jeffrey Tyner, Srđan Verstovšek, Wei Wang, Brent L. Wood, Wenbin Xiao, Cecilia C.S. Yeung, Andreas Hochhaus - Leukemia 2022 cited by 3,904

  2. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

    Authors: Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle, Iguaracyra Araújo, Emilio Berti, Govind Bhagat, Anita Borges, Daniel F. Boyer, Maria Calaminici, Amy Chadburn, John K. C. Chan, Wah Cheuk, Wee Joo Chng, John Choi, Shih‐Sung Chuang, Sarah E. Coupland, Magdalena Czader, Sandeep S. Davé, Daphne de Jong, Ming‐Qing Du, Kojo S.J. Elenitoba‐Johnson, Judith A. Ferry, Julia T. Geyer, Dita Gratzinger, Joan Guitart, Sumeet Gujral, Marian H. Harris, Christine J. Harrison, Sylvia Hartmann, Andreas Hochhaus, Patty M. Jansen, Kennosuke Karube, Werner Kempf, Joseph D. Khoury, Hiroshi Kimura, Wolfgang Hiddemann, Alexandra E. Kovach, Shaji Kumar, Alexander J. Lazar, Stefano Lazzi, Lorenzo Leoncini, Nelson Leung, Vasiliki Leventaki, Xiao‐Qiu Li, Megan S. Lim, Weiping Liu, Abner Louissaint, Andrea N. Marcogliese, L. Jeffrey Medeiros, Michael Michal, Roberto N. Miranda, Christina Mitteldorf, Santiago Montes‐Moreno, William G. Morice, Valentina Nardi, Kikkeri N. Naresh, Yasodha Natkunam, Siok‐Bian Ng, Ilske Oschlies, German Ott, Marie Parrens, Melissa Pulitzer, S. Vincent Rajkumar, Andy C. Rawstron, Karen L. Rech, Andreas Rosenwald, Jonathan Said, Clémentine Sarkozy, Shahin Sayed, Caner Saygin, Anna Schuh, William A. Sewell, Reiner Siebert, Aliyah R. Sohani, Reuben Tooze, Alexandra Traverse‐Glehen, Francisco Vega, B. Vergier, Ashutosh Wechalekar, Brent L. Wood, Luc Xerri, Wenbin Xiao - Leukemia 2022 cited by 3,736

  3. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Authors: Andreas Hochhaus, Michele Baccarani, Richard T. Silver, CA Schiffer, Jane F. Apperley, Francisco Cervantes, R E Clark, J. E. Cortes, Michael W. Deininger, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, J. Janssen, Hagop M. Kantarjian, D. W. Kim, Richard A. Larson, J. H. Lipton, F.-X. Mahon, Jiří Mayer, Franck E. Nicolini, D Niederwieser, Fabrizio Pane, Jerald P. Radich, Delphine Réa, Johan Richter, G Rosti, Philipe Rousselot, Giuseppe Saglio, Susanne Saußele, Simona Soverini, J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann - Leukemia 2020 cited by 1,510

  4. Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

    Authors: Helmut Oettle, P. Neuhaus, Andreas Hochhaus, Jörg T. Hartmann, Klaus Gellert, Karsten Ridwelski, Marco Niedergethmann, C. Zülke, Jörg Fahlke, M. Arning, Marianne Sinn, Axel Hinke, Hanno Riess - JAMA 2013 cited by 1,801

  5. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    Authors: Delphine Réa, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, Jane F. Apperley, André Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saußele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Koji Sasaki, Lynette Chee, Valentín García‐Gutiérrez, Jörge E. Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus - Blood 2021 cited by 336

  6. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Authors: Andreas Hochhaus, Richard A. Larson, François Guilhot, Jerald P. Radich, Susan Branford, Timothy P. Hughes, Michele Baccarani, Michael W. Deininger, Francisco Cervantes, Satoko Fujihara, Christine-Elke Ortmann, Hans D. Menssen, Hagop Kantarjian, Stephen G. O’Brien, Brian Druker - New England Journal of Medicine 2017 cited by 1,259

  7. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

    Authors: Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, Hironobu Minami, Delphine Réa, Daniel J. DeAngelo, Massimo Breccia, Yeow-Tee Goh, Moshe Talpaz, Andreas Hochhaus, Philipp le Coutre, Oliver G. Ottmann, Michael C. Heinrich, Juan Luis Steegmann, Michael W. Deininger, Jeroen J. W. M. Janssen, François-Xavier Mahon, Yosuke Minami, David T Yeung, David M. Ross, Martin S. Tallman, Jae H. Park, Brian Druker, David Hynds, Yuyan Duan, Christophe Meille, Florence Hourcade‐Potelleret, K. Gary J. Vanasse, Fabian Lang, Dong‐Wook Kim - New England Journal of Medicine 2019 cited by 467

  8. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Authors: Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Siu‐Fun Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah, Hagop M. Kantarjian - New England Journal of Medicine 2013 cited by 1,124

  9. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Authors: Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian - Blood 2018 cited by 583

  10. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Authors: Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian, Michele Baccarani, Jiřı́ Mayer, Concepción Boqué, Neil P. Shah, Charles Chuah, Luís Casanova, Brigid Bradley-Garelik, George Manos, Andreas Hochhaus - Journal of Clinical Oncology 2016 cited by 946

  11. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    Authors: Brian Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson - New England Journal of Medicine 2006 cited by 3,481

  12. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

    Authors: Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jörge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong‐Wook Kim, André Abdo, Laura Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saußele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentín García‐Gutiérrez, S. S. Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J. Mauro - Leukemia 2023 cited by 135

  13. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

    Authors: Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson, Dong‐Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Étienne, Carla Boquimpani, Ricardo Pasqüini, Richard E. Clark, Viviane Dubruille, Ian W. Flinn, Sławomira Kyrcz‐Krzemień, Ewa Mędraś, Maria Aparecida Zanichelli, Israel Bendit, Silvia Cacciatore, Ksenia Titorenko, Paola Aimone, Giuseppe Saglio, Andreas Hochhaus - Leukemia 2021 cited by 351

  14. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    Authors: Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong‐Wook Kim, Iryna Dyagil, Nataliia Glushko, Dragana Milojković, Philipp le Coutre, Valentín García‐Gutiérrez, Laurence Reilly, Allison Jeynes-Ellis, Eric Leip, Nathalie Bardy‐Bouxin, Andreas Hochhaus, Tim H. Brümmendorf - Journal of Clinical Oncology 2017 cited by 493

  15. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

    Authors: Jörge E. Cortes, Jane F. Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Arthur, Lori J. Maness, Moshe Talpaz, Michael J. Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger - Blood 2021 cited by 193

  16. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Authors: Stephen G. O’Brien, François Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy P. Hughes, Klaus Lechner, Johan Lanng Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John D. Shepherd, Bengt Simonsson, Aloïs Gratwohl, John M. Goldman, Hagop M. Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, Brian Druker - New England Journal of Medicine 2003 cited by 3,565

  17. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

    Authors: Susanne Saußele, Johan Richter, Joëlle Guilhot, Franz Gruber, Henrik Hjorth-Hansen, António Almeida, Jeroen J. W. M. Janssen, Jiřı́ Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson‐Strömberg, Joaquín Martínez‐López, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Kateřina Machová Poláková, Martin C. Müller, Satu Mustjoki, Marc Berger, Alice Fabarius, Wolf‐Karsten Hofmann, Andreas Hochhaus, Markus Pfirrmann, François‐Xavier Mahon, Gert J. Ossenkoppele, Maria Pagoni, Stina Söderlund, Martine Escoffre‐Barbe, Gabriel Étienne, Jolanta Dengler, Françoise Huguet, Nikolas von Bubnoff, Hana Klamová, Edgar Faber, François Guilhot, Kourosh Lotfi, Delphine Réa, Tim H. Brümmendorf, G.E. de Greef, Leif Stenke, Franck E. Nicolini, Laurence Legros, Andreas Burchert, J Voglová, Aude Charbonnier, Emmanuel Gyan, Volker Kunzmann, Peter E. Westerweel - The Lancet Oncology 2018 cited by 611

  18. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

    Authors: Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes, Richard A. Larson, D-W Kim, Surapol Issaragrisil, Philipp D. le Coutre, Gabriel Étienne, P.E. Dorlhiac‐Llacer, Richard E. Clark, Ian W. Flinn, Hirohisa Nakamae, Breanne Donohue, Weiping Deng, Darshan Dalal, Hans D. Menssen, Hagop M. Kantarjian - Leukemia 2016 cited by 850

  19. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

    Authors: Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil, P. Le Coutre, Gabriel Étienne, Clarisse Lobo, Ricardo Pasqüini, Richard E. Clark, Andreas Hochhaus, Timothy P. Hughes, Neil J. Gallagher, Albert Hoenekopp, Mei Dong, Md Ariful Haque, Richard A. Larson, Hagop M. Kantarjian - New England Journal of Medicine 2010 cited by 1,679

  20. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    Authors: Tim H. Brümmendorf, Jörge E. Cortes, Dragana Milojković, Carlo Gambacorti‐Passerini, Richard E. Clark, Philipp le Coutre, Valentín García‐Gutiérrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Rafael Hurtado Monroy, Eric Leip, Simon Purcell, Anne Yver, Andrea Viqueira, Michael W. Deininger, BFORE study investigators - Leukemia 2022 cited by 141

  21. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Authors: Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus, Jörge E. Cortes, Sandip Shah, Manuel Ayala, Beatriz Moiraghi, Zhixiang Shen, Jiřı́ Mayer, Ricardo Pasqüini, Hirohisa Nakamae, Françoise Huguet, Concepción Boqué, Charles Chuah, Eric Bleickardt, M. Brigid Bradley‐Garelik, Chao Zhu, Ted P. Szatrowski, Д. А. Шапиро, Michele Baccarani - New England Journal of Medicine 2010 cited by 1,582

  22. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

    Authors: Franziska Taube, Julia Annabell Georgi, Michael Krämer, Sebastian Stasik, Jan Moritz Middeke, Christoph Röllig, Utz Krug, Alwin Krämer, Sebastian Scholl, Andreas Hochhaus, Tim H. Brümmendorf, Ralph Naumann, A. Petzold, Roger Mulet‐Lazaro, Peter J.M. Valk, Björn Steffen, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schäfer‐Eckart, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Richard Noppeney, Ulrich Kaiser, Claudia D. Baldus, Martin Kaufmann, Sylvia Herold, Friedrich Stölzel, Katja Sockel, Malte von Bonin, Carsten Müller‐Tidow, Uwe Platzbecker, Wolfgang E. Berdel, Hubert Serve, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Christian Thiede, for the Study Alliance Leukemia (SAL) - Blood 2021 cited by 164

  23. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

    Authors: Andreas Hochhaus, Jianxiang Wang, Dong‐Wook Kim, Dennis Dong Hwan Kim, Jiřı́ Mayer, Yeow‐Tee Goh, Philipp le Coutre, Naoto Takahashi, In Ho Kim, Gabriel Étienne, David Andorsky, Ghayas C. Issa, Richard A. Larson, Felice Bombaci, S. S. Kapoor, Tracey McCulloch, Kamel Malek, Lillian Yau, Sophie Ifrah, Matthias Hoch, Jörge E. Cortes, Timothy P. Hughes - New England Journal of Medicine 2024 cited by 139

  24. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

    Authors: for the SAKK and the German CML Study Group, Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele, Markus Pfirrmann, Stefan W. Krause, Hans‐Jochem Kolb, Andreas Neubauer, Dieter K. Hossfeld, C. Nerl, Aloïs Gratwohl, Gabriela M. Baerlocher, Dominik Heim, Tim H. Brümmendorf, Alice Fabarius, Claudia Haferlach, Brigitte Schlegelberger, Marcus Müller, Sabine Jeromin, Ulrike Proetel, Katharina Kohlbrenner, Astghik Voskanyan, Sébastien Rinaldetti, Wolfgang Seifarth, Birgit Spieß, Leopold Balleisen, M-E Goebeler, Mathias Hänel, Anthony D. Ho, Jolanta Dengler, Christiane Falge, Lothar Kanz, Stephan Kremers, Andreas Burchert, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, H. W. Lindemann, Cornelius F. Waller, M. Pfreundschuh, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiřı́ Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland J. Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, W. Gaßmann, Antonio Pezzutto, Michael Schenk, Peter Brossart, Thomas Geer, Stephan Bildat, E. Schäfer, Andreas Hochhaus, Joerg Hasford - Leukemia 2017 cited by 339